BioElectronics Worldwide  Class IIa OTC Market Clearances

US FDA – The treatment of edema following blepharoplasty.

• ActiPatch® OTC indication-of-use: Adjunctive treatment of musculoskeletal pain related to: (1) Plantar Fasciitis of the heel; and (2) Osteoarthritis of the Knee
  For the official letter, Click Here

US FDA (Pending) –

• RecoveryRx® Indication-of-use: Postoperative pain and edema.
• ActiPatch® OTC indication-of-use: Relief of musculoskeletal pain.
• Allay® OTC indication-of-use: Relief of menstrual pain and discomfort.

NHS- Addition to the Drug Tariff IX April 2018. For the official letter, Click Here

European Union (CE) – For the reduction of pain and Inflammation (OTC).

Health Canada – Relief of pain associated with musculoskeletal complaints, relief of menstrual pain, and postoperative OTC.

Australia (TGA) – For the reduction of pain and inflammation.

Korea – Reduction of muscle pain.

Many others around the world.